PLD
48
-5
CTAS
59
4
UNP
45
6
ICE
62
3
MRO
40
-15
DE
56
10
FLS
75
2
CNP
63
3
RRC
59
-4
HP
45
4
SHW
65
7
PVH
57
5
DHR
38
3
AVB
64
4
LRCX
45
6
BXP
52
2
COP
54
-2
MRK
27
5
ALL
51
8
SWKS
49
11
PLD
48
-5
CTAS
59
4
UNP
45
6
ICE
62
3
MRO
40
-15
DE
56
10
FLS
75
2
CNP
63
3
RRC
59
-4
HP
45
4
SHW
65
7
PVH
57
5
DHR
38
3
AVB
64
4
LRCX
45
6
BXP
52
2
COP
54
-2
MRK
27
5
ALL
51
8
SWKS
49
11
Financhill
Back

Entrada Therapeutics 10K Form

Buy
58

TRDA
Entrada Therapeutics

Last Price:
18.75
Seasonality Move:
-29.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TRDA News And Ratings

See the #1 stock for the next 7 days that we like better than TRDA

TRDA Financial Statistics

Sales & Book Value

Annual Sales: $129.01M
Cash Flow: $-24.91M
Price / Cash Flow: 0
Annual Sales: $11.30
Price / Book: 1.6

Profitability

EPS (TTM): 1.59000
Net Income (TTM): $54.95M
Gross Margin: --
Return on Equity: 17.06%
Return on Assets: 10.56%

Entrada Therapeutics Earnings Forecast

Key Entrada Therapeutics Financial Ratios

  • The Research & Development expenses have been 77.42% of Revenue.
  • The Net Earning history of TRDA is -5.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Entrada Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TRDA
Website: entradatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.59
Quick Ratio: 6.4

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TRDA Technical Analysis vs Fundamental Analysis

Buy
58
Entrada Therapeutics (TRDA) is a Buy

Is Entrada Therapeutics a Buy or a Sell?